Key result
Low-molecular-weight heparins are recommended for the treatment and prevention of venous thromboembolism in cancer patients, with nurses playing a key role in implementation and patient education.
Highlights the importance of low-molecular-weight heparins and the critical role of nursing in managing and preventing VTE in cancer patients.
Answers are grounded in this paper and cite their sources.
Supports nurse education on LMWH for cancer VTE; leaves open optimal implementation strategies pending prospective trials.
Venous thromboembolism (VTE), encompassing deep venous thrombosis and pulmonary embolism (PE), is a common complication of cancer and an important cause of preventable mortality in people with cancer. Because VTE can be clinically silent, fatal PE generally occurs without warning, and preventive measures are, therefore, necessary in high-risk patients. Clinical guidelines recommend the use of low-molecular-weight heparins in the treatment and prevention of VTE in patients with cancer, in addition to non-pharmacological interventions aimed at reducing thrombotic risk. Nurses have an important role in helping to identify patients at risk of developing VTE, and in the implementation of preventive or therapeutic regimens, and monitoring the development of complications. Furthermore, nurses are in an ideal position to educate patients on the importance of preventive measures and to help ensure compliance with thromboprophylactic interventions.
No takes yet. Share an insight, caveat, or question.
Dolan et al. (2007) conducted a review in Venous thromboembolism in cancer patients. Low-molecular-weight heparins and nursing care was evaluated. Low-molecular-weight heparins are recommended for the treatment and prevention of venous thromboembolism in cancer patients, with nurses playing a key role in implementation and patient education.
Synapse has enriched 10 related papers. Consider them for comparative context: